| Literature DB >> 17504204 |
Marina Protopopova1, Elena Bogatcheva, Boris Nikonenko, Sam Hundert, Leo Einck, Carol A Nacy.
Abstract
The last 10 years have seen resurgent industry activity in discovery and development of new drugs for the treatment of tuberculosis (TB), a growing widespread and devastating (more than 2 million deaths annually) bacterial infection that is of increasing concern in developing and developed nations alike. This review describes drugs currently being evaluated in the clinic for treatment of uncomplicated and drug resistant pulmonary TB, and updates the literature on 5 new drugs that entered clinical trials in the last 4 years.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17504204 DOI: 10.2174/157340607780620626
Source DB: PubMed Journal: Med Chem ISSN: 1573-4064 Impact factor: 2.745